- Home
- PAVM vs GTBP Comparison
PAVM vs GTBP Comparison
Compare PAVM & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVM
- GTBP
- Stock Information
- Founded
- PAVM 2014
- GTBP 1965
- Country
- PAVM United States
- GTBP United States
- Employees
- PAVM N/A
- GTBP N/A
- Industry
- PAVM Medical/Dental Instruments
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- PAVM Health Care
- GTBP Health Care
- Exchange
- PAVM Nasdaq
- GTBP Nasdaq
- Market Cap
- PAVM 12.0M
- GTBP 5.5M
- IPO Year
- PAVM 2016
- GTBP N/A
- Fundamental
- Price
- PAVM $0.58
- GTBP $2.00
- Analyst Decision
- PAVM Strong Buy
- GTBP Strong Buy
- Analyst Count
- PAVM 1
- GTBP 1
- Target Price
- PAVM $19.00
- GTBP $11.00
- AVG Volume (30 Days)
- PAVM 128.7K
- GTBP 108.9K
- Earning Date
- PAVM 08-11-2025
- GTBP 08-13-2025
- Dividend Yield
- PAVM N/A
- GTBP N/A
- EPS Growth
- PAVM N/A
- GTBP N/A
- EPS
- PAVM 0.96
- GTBP N/A
- Revenue
- PAVM $1,993,000.00
- GTBP N/A
- Revenue This Year
- PAVM N/A
- GTBP N/A
- Revenue Next Year
- PAVM $455.63
- GTBP N/A
- P/E Ratio
- PAVM $0.62
- GTBP N/A
- Revenue Growth
- PAVM N/A
- GTBP N/A
- 52 Week Low
- PAVM $0.54
- GTBP $1.72
- 52 Week High
- PAVM $1.90
- GTBP $4.10
- Technical
- Relative Strength Index (RSI)
- PAVM 42.49
- GTBP 34.07
- Support Level
- PAVM $0.54
- GTBP $1.91
- Resistance Level
- PAVM $0.62
- GTBP $2.31
- Average True Range (ATR)
- PAVM 0.03
- GTBP 0.31
- MACD
- PAVM 0.00
- GTBP -0.14
- Stochastic Oscillator
- PAVM 44.77
- GTBP 4.64
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.